Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Once-a-day Regimen or Steroid Withdrawal in de Novo Kidney Transplant Recipients Treated With Everolimus, Cyclosporine and Steroids: a 12-month, Prospective, Randomized, Multicenter, Open-label Study. The EVIDENCE Study (EVerolImus Once-a-Day rEgimen With Neoral Versus Corticosteroid Elimination).

NCT01023815 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT01023815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01023815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Once-a-day Regimen or Steroid Withdrawal in de Novo Kidney Transplant Recipients Treated With Everolimus, Cyclosporine and Steroids: a 12-month, Prospective, Randomized, Multicenter, Open-label Study. The EVIDENCE Study (EVerolImus Once-a-Day rEgimen With Neoral Versus Corticosteroid Elimination).
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2009
Completion date
July 31, 2012
Enrollment
330 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

de novo kidney transplant recipients, renal transplantation